Open Access
Subscription Access
An Essential Parameters of Simvastatin Include Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications and Toxicity
Abstract
An oral HMG-CoA reductase inhibitor called simvastatin is prescribed as a dietary supplement. It is a semi-synthetic version of the first FDA-approved statin, lovastatin. Simvastatin helps reduce the synthesis of cholesterol and issues related to dyslipidemia. High concentrations of LDL cholesterol can result in artery damage, leading to cardiac complications and stroke in a potential manner. Whatever it may be there are several more effective statins along with more favorable adverse effect profiles. In order for clinicians to guide patient care for the treatment of hyperlipidemia as part of the interprofessional team, this activity explains the indications, mechanism of action, methods of administration, important adverse effects, contraindications, and monitoring of simvastatin.
References
Gryn, S. E., & Hegele, R. A. (2015). Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 16(8), 1255–1262.
De Denus, S., & Spinler, S. A. (2002). Early statin therapy for acute coronary syndromes. Annals of Pharmacotherapy, 36(11), 1749–1758.
Trias, F., Pintó, X., Corbella, E., Suárez-Tembra, M., Ruíz-García, A., Díaz-Díaz, J. L., Sánchez-Ruíz-Granado, E., Sarasa, I., Martínez-Porqueras, R., Rodríguez-Sánchez, M. A., & Corbella, X. (2022). Differences in the diabetogenic effect of statins in patients with prediabetes: The PRELIPID study. Medicina Clínica, 158(11), 531–539.
Chochola, M., Lubanda, J. C., Skalicka, L., Varejka, P., Horejs, J., Prskavec, T., Balík, M., Semrád, M., & Linhart, A. (2008). Bilateral leg compartment syndrome due to severe myonecrosis caused by inappropriate use of simvastatin. Journal des Maladies Vasculaires, 33(4–5), 229–233.
Parkin, L., Paul, C., & Herbison, G. P. (2014). Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data. International Journal of Cardiology, 174(1), 83–89.
Somagutta, M. K. R., Shama, N., Pormento, M. K. L., Jagani, R. P., Ngardig, N. N., Ghazarian, K., Mahmutaj, G., El-Faramawy, K., Mahadevaiah, A., & Jain, M. S. (2022). Statin-induced necrotizing autoimmune myopathy: A systematic review. Reumatologia, 60(1), 63–69.
Lee, J. W., Morris, J. K., & Wald, N. J. (2016). Grapefruit juice and statins. American Journal of Medicine, 129(1), 26–29.
Russi, G. (2015). Severe dyslipidemia in pregnancy: The role of therapeutic apheresis. Transfusion and Apheresis Science, 53(3), 283–287.
Comparison table: Some lipid-lowering drugs. (2019). Medical Letter on Drugs and Therapeutics, 61(1565), e24–e30.
Calderon, R. M., Cubeddu, L. X., Goldberg, R. B., & Schiff, E. R. (2010). Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma. Mayo Clinic Proceedings, 85(4), 349–356.
Laufs, U., Weingärtner, O., Kassner, U., & Schatz, U. (2022). State of the art: Statin therapy. Deutsche Medizinische Wochenschrift, 147(1–2), 62–68.
Page, S. R., & Yee, K. C. (2014). Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Internal Medicine Journal, 44(7), 690–693.
Taylor, B. A., Panza, G., & Thompson, P. D. (2016). Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms. International Journal of Cardiology, 209, 12–13.
Liao, J. K. (2007). Safety and efficacy of statins in Asians. American Journal of Cardiology, 99(3), 410–414.
Hamadouk, R. M., Albashair, E. D., Mohammed, F. M., & Yousef, B. A. (2022). The practice of community pharmacists in managing potential drug-drug interactions: A simulated patient visits study. Integrated Pharmacy Research and Practice, 11, 71–84.
Hess, D. C., & Fagan, S. C. (2001). Pharmacology and clinical experience with simvastatin. Expert Opinion on Pharmacotherapy, 2(1), 153–163.
Refbacks
- There are currently no refbacks.